Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Ítems similars

• Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
  per: Mathisen, Michael S., et al.
  Publicat: (2011)
• Outcomes of Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
  per: Maiti, Abhishek, et al.
  Publicat: (2020)
• Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
  per: Quintás-Cardama, Alfonso, et al.
  Publicat: (2009)
• Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
  per: Jabbour, Elias, et al.
  Publicat: (2008)
• Estimations of the Increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors Therapy
  per: Huang, Xuelin, et al.
  Publicat: (2012)